3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
5
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
6
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Skin Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Micrometastasis
1
Lymphatic Metastasis
1
Inflammatory Breast Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
24
Nivolumab
13
atezolizumab
7
Ipilimumab
6
Cyclophosphamide
6
fludarabine
5
Specimen Handling
5
Magnetic Resonance Spectroscopy
5
aldesleukin
4
Interleukin-2
4
Biopsy
4
durvalumab
3
cemiplimab
3
Docetaxel
3
tislelizumab
2
osimertinib
2
fludarabine phosphate
2
enzalutamide
2
avelumab
2
X-Rays
2
Ritonavir
2
Radiotherapy
2
Observation
2
Methods
2
Immunoglobulin G
2
IFL protocol
2
Drug Therapy
2
zimberelimab
1
utomilumab
1
ulixertinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Indocyanine Green
×
Dermatologic
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled